Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.46 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.46 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL8961491 | 0.98 | OPRM1 (0.47) | OPRM1OPRD1OPRK1TSHRALDH1A1 | |
| SCHEMBL479112 | 0.98 | OPRM1 (0.47) | OPRM1OPRD1OPRK1TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL144177 | 0.98 | OPRM1 (0.50) | OPRM1OPRD1OPRK1TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL334991 | 0.95 | OPRM1 (0.49) | OPRM1OPRD1OPRK1TSHRALDH1A1 | |
| SCHEMBL2795989 | 0.93 | OPRM1 (0.44) | OPRM1OPRD1OPRK1TSHRALDH1A1 | |
| SCHEMBL29151407 | 0.91 | OPRM1 (0.49) | OPRM1OPRD1OPRK1TSHRALDH1A1 | |
| SCHEMBL16104361 | 0.89 | CARM1 (0.55) | OPRM1OPRD1OPRK1TSHRALDH1A1 | |
| SCHEMBL17195397 | 0.89 | HTT (0.56) | OPRM1OPRD1OPRK1TSHRALDH1A1 | |
| SCHEMBL8021687 | 0.89 | TSHR (0.59) | OPRM1TSHRALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL11197923 | 0.89 | HRH3 (0.59) | OPRM1OPRD1TSHRALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 650 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851627-B2 | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2010-12-14 | — | — | US | claimed |
| US-20090221823-A1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2009-09-03 | — | — | US | claimed |
| EP-1963296-A2 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) | 2008-09-03 | — | — | EP | claimed |
| EP-1888559-A2 | PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR | Wyeth a Corporation of the State of Delaware (US) | 2008-02-20 | — | — | EP | claimed |
| WO-2007066163-A2 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvanosan Mukodo Reszvenytarsasag (HU) | 2007-06-14 | — | — | WO | claimed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | claimed |
| WO-2006135839-A2 | PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR | WYETH (US) | 2006-12-21 | — | — | WO | claimed |
| US-4748276-A | Process for preparing N,N-bis(2-hydroxyethyl)benzylamine and N,N-bis(2-chloroethyl)benzylamine | STERLING DRUG INC. (US) | 1988-05-31 | — | — | US | claimed |
| US-4439380-A | Photopolymerizable composition, especially for dental purposes | ETABLISSEMENT DENTAIRE IVOCLAR (LI) | 1984-03-27 | — | — | US | claimed |
| WO-2026098493-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2026-05-15 | — | — | WO | disclosed |
| EP-3941459-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4713313-A2 | TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | Springworks Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12564591-B2 | HCK as a therapeutic target in MYD88 mutated diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-4056538-A | ANTIDEPRESSANTS, ANTIULCER AGENTS | AYERST, MCKENNA & HARRISON LIMITED (CA) | 1977-11-01 | — | — | US | disclosed |
| US-4041169-A | TREATING AND PREVENTING ULCERS | AYERST MCKENNA AND HARRISON LTD. (CA) | 1977-08-09 | — | — | US | disclosed |
| US-4012511-A | ANTIULCER AGENTS | AYERST MCKENNA & HARRISON LTD. (CA) | 1977-03-15 | — | — | US | disclosed |
| US-4003913-A | ANTIDEPRESSANTS, ANTIULCER AGENTS | AYERST MCKENNA AND HARRISON LTD. (CA) | 1977-01-18 | — | — | US | disclosed |
| US-3995052-A | Indenopyran- and indenothiopyranalkylamines III in the treatment of depression | AYERST MCKENNA AND HARRISON LTD. (CA) | 1976-11-30 | — | — | US | disclosed |
| US-3962236-A | ANTIDEPRESSANTS, ANTI-ULCER | AYERST MCKENNA AND HARRISON LTD. (CA) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | HTR5A, HTR2C, HTR1D | OPRM1 91/4885OPRD1 62/4885OPRK1 66/4885 |
| US-20090221823-A1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | HRH4, HRH1, HRH2 | OPRM1 216/4885OPRD1 240/4885OPRK1 185/4885 |
| US-12564591-B2 | HCK as a therapeutic target in MYD88 mutated diseases | HCK, BTK, LYN | OPRM1 2259/4885OPRD1 3454/4885OPRK1 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.